78 / 89
78
78.
Wigley FM, Seibold JR, Wise RA, McCloskey
DA, Dole WP. Intravenous iloprost treatment of
Raynaud's phenomenon and ischemic ulcers
secondary to systemic sclerosis. J Rheumatol
1992;19:1407-14.
79.
Langevitz P, Buskila D, Lee P, Urowitz MB.
Treatment of refractory ischemic skin ulcers in
patients with Raynaud´s phenomenon with
PGE1 infusions. J Rheumatol 1989;16:1433-5.
80.
Marasini B, Massarotti M, Bottasso B, Coppola
R, Papa ND, Maglione W, et al. Comparison
between iloprost and alprostadil in the
treatment of Raynaud's phenomenon. Scand J
Rheumatol 2004;33:253-6.
81.
Matucci-Cerinic M, Denton CP, Furst DE, Mayes
MD, Hsu VM, Carpentier P, et al. Bosentan
treatment of digital ulcers related to systemic
sclerosis:
results
from
the
RAPIDS-2
randomised, double-blind, placebo-controlled
trial. Ann Rheum Dis 2011;70:32-8.
82.
Korn JH, Mayes M, Matucci Cerinic M, Rainisio
M, Pope J, Hachulla E, et al. Digital ulcers in
systemic sclerosis: prevention by treatment with
bosentan, an oral endothelin receptor
antagonist. Arthritis Rheum 2004;50:3985-93.
83.
Brueckner CS, Becker MO, Kroencke T, Huscher
D, Scherer HU, Worm M, et al. Effect of
sildenafil on digital ulcers in systemic sclerosis:
analysis from a single centre pilot study. Ann
Rheum Dis 2010;69:1475-8.